• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拒绝生物等效性时概率的计算。

The calculation of probabilities in rejecting bioequivalence.

作者信息

Yee K F

出版信息

Biometrics. 1986 Dec;42(4):961-5.

PMID:3814736
Abstract

Methods are given for deriving the lower and upper bounds of the probabilities for rejecting bioequivalence. Except when two formulations are nearly equal, the lower and upper bounds become very close and thus give an exact probability. The methods can be used in two- or higher-way crossover or parallel groups designs. One can also determine the sample size from the equations. The results are compared with the probabilities obtained by simulation.

摘要

给出了推导拒绝生物等效性概率的下限和上限的方法。除非两种制剂几乎相等,下限和上限会变得非常接近,从而给出精确概率。这些方法可用于双向或更高阶交叉或平行组设计。也可以从这些方程中确定样本量。将结果与通过模拟获得的概率进行比较。

相似文献

1
The calculation of probabilities in rejecting bioequivalence.拒绝生物等效性时概率的计算。
Biometrics. 1986 Dec;42(4):961-5.
2
A Bayesian analysis of the two-period crossover design for clinical trials.用于临床试验的两阶段交叉设计的贝叶斯分析。
Biometrics. 1985 Dec;41(4):979-90.
3
The relative efficiency of Zelen's prerandomization design for clinical trials.
Biometrics. 1983 Sep;39(3):711-8.
4
Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.基于二次损失函数的贝叶斯决策理论组序贯临床试验设计:频率学派评估
Clin Trials. 2007;4(1):5-14. doi: 10.1177/1740774506075764.
5
Exact one-sided confidence limits for the difference between two correlated proportions.两个相关比例差异的精确单侧置信限。
Stat Med. 2007 Aug 15;26(18):3369-84. doi: 10.1002/sim.2708.
6
Event-tree analysis with imprecise probabilities.事件树分析与不精确概率。
Risk Anal. 2012 Feb;32(2):330-44. doi: 10.1111/j.1539-6924.2011.01721.x. Epub 2011 Nov 6.
7
Sample size calculation for the Power Model for dose proportionality studies.剂量比例研究的功效模型的样本量计算。
Pharm Stat. 2007 Jan-Mar;6(1):35-41. doi: 10.1002/pst.241.
8
[The parasite capacity of the host population].[宿主群体的寄生虫感染能力]
Parazitologiia. 2002 Jan-Feb;36(1):48-59.
9
Sequential design approaches for bioequivalence studies with crossover designs.交叉设计生物等效性研究的序贯设计方法。
Pharm Stat. 2008 Oct-Dec;7(4):245-62. doi: 10.1002/pst.294.
10
Implementing type I & type II error spending for two-sided group sequential designs.在双侧成组序贯设计中实施I型和II型错误消耗。
Contemp Clin Trials. 2008 May;29(3):351-8. doi: 10.1016/j.cct.2007.09.002. Epub 2007 Sep 21.

引用本文的文献

1
Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers.健康志愿者中口服泛昔洛韦与别嘌醇之间不存在药代动力学相互作用。
Eur J Clin Pharmacol. 1994;46(4):355-9. doi: 10.1007/BF00194405.
2
Clinical pharmacological equivalence of a novel FCH-free GTN spray with low ethanol content vs a FCH-containing GTN spray.一种新型低乙醇含量无氟氯烃硝酸甘油喷雾剂与含氟氯烃硝酸甘油喷雾剂的临床药理等效性。
Eur J Clin Pharmacol. 1995;47(5):437-43. doi: 10.1007/BF00196858.